Opinion

Video

Strategies for Managing Treatment-Naïve CLL with High-Risk Features

Author(s):

Catherine C. Coombs, MD,Brian T. Hill, MD, PhD

Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.

Related Videos
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Richard Kim, MD, Moffitt Cancer Center
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Tiago Biachi, MD, PhD
Related Content
CLL, Image credit: LASZLO– stock.adobe.com
November 20th 2024

Lisaftoclax NDA Accepted for Review in China for Relapsed/Refractory CLL/SLL

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

Chronic Lymphocytic Leukemia
November 13th 2024

Piecing Together the Proper BTK Usage in CLL

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

OncLive's Top 5 Stories of the Week in Oncology
November 9th 2024

The OncFive: Top Oncology Articles for the Week of 11/3

Matthew Cortese, MD, MPH, assistant professor, oncology, Department of Medicine-Lymphoma, Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center
November 6th 2024

Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024